Literature DB >> 23732052

Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy.

Maria M Gramatges1, Alison A Bertuch.   

Abstract

Telomeres are DNA-protein structures that form a protective cap on chromosome ends. As such, they prevent the natural ends of linear chromosomes from being subjected to DNA repair activities that would result in telomere fusion, degradation, or recombination. Both the DNA and protein components of the telomere are required for this essential function, because insufficient telomeric DNA length, loss of the terminal telomeric DNA structure, or deficiency of key telomere-associated factors may elicit a DNA damage response and result in cellular senescence or apoptosis. In the setting of failed checkpoint mechanisms, such DNA-protein defects can also lead to genomic instability through telomere fusions or recombination. Thus, as shown in both model systems and in humans, defects in telomere biology are implicated in cellular and organismal aging as well as in tumorigenesis. Bone marrow failure and malignancy are 2 life-threatening disease manifestations in the inherited telomere biology disorder dyskeratosis congenita. We provide an overview of basic telomere structure and maintenance. We outline the telomere biology defects observed in dyskeratosis congenita, focusing on recent discoveries in this field. Last, we review the evidence of how telomere biology may impact sporadic aplastic anemia and the risk for various cancers.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  AML; CLL; CST; CTC1; CTC1/STN1/TEN1; DC; FA; FISH; Fanconi anemia; MDS; O/E; POT1; Q-PCR; RAP1; RTEL1; STN1; TEN1; TERC; TERF1 (TRF1)-interacting nuclear factor 2; TERT; TIN2; TIN2-interacting protein 1; TINF2; TPP1; TRF1; TRF1-interacting protein 2; TRF2; acute myeloid leukemia; base pairs; bp; chronic lymphocytic leukemia; conserved telomere maintenance component 1; dyskeratosis congenita; fluorescence in situ hybridization; myelodysplastic syndrome; odds over expected ratio; protection of telomeres 1; quantitative polymerase chain reaction; regulator of telomere elongation helicase 1; repressor/activator protein 1; suppressor of cdc13-1; telomerase RNA component; telomerase reverse transcriptase; telomeric pathway with STN1; telomeric repeat factor 1; telomeric repeat factor 2

Mesh:

Substances:

Year:  2013        PMID: 23732052      PMCID: PMC3834083          DOI: 10.1016/j.trsl.2013.05.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   10.171


  111 in total

1.  Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

Authors:  R T Calado; J N Cooper; H M Padilla-Nash; E M Sloand; C O Wu; P Scheinberg; T Ried; N S Young
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

2.  CTC1 Mutations in a patient with dyskeratosis congenita.

Authors:  Rachel B Keller; Katelyn E Gagne; G Naheed Usmani; George K Asdourian; David A Williams; Inga Hofmann; Suneet Agarwal
Journal:  Pediatr Blood Cancer       Date:  2012-04-24       Impact factor: 3.167

3.  What are the essential symptoms in the Hoyeraal-Hreidarsson syndrome?

Authors:  S Ohga; T Kai; K Honda; H Nakayama; T Inamitsu; K Ueda
Journal:  Eur J Pediatr       Date:  1997-01       Impact factor: 3.183

4.  Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening.

Authors:  V L Makarov; Y Hirose; J P Langmore
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 5.  Haploinsufficiency and telomere length homeostasis.

Authors:  Lea Harrington
Journal:  Mutat Res       Date:  2011-11-07       Impact factor: 2.433

6.  Mutations in the telomere capping complex in bone marrow failure and related syndromes.

Authors:  Amanda J Walne; Tanya Bhagat; Michael Kirwan; Cyril Gitiaux; Isabelle Desguerre; Norma Leonard; Elena Nogales; Tom Vulliamy; Inderjeet S Dokal
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

7.  Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10.

Authors:  V Pogacić; F Dragon; W Filipowicz
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

8.  Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita.

Authors:  Bari J Ballew; Meredith Yeager; Kevin Jacobs; Neelam Giri; Joseph Boland; Laurie Burdett; Blanche P Alter; Sharon A Savage
Journal:  Hum Genet       Date:  2013-01-18       Impact factor: 4.132

9.  Dyskeratosis Congenita (DC) Registry: identification of new features of DC.

Authors:  S Knight; T Vulliamy; A Copplestone; E Gluckman; P Mason; I Dokal
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

10.  Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a).

Authors:  Utz Herbig; Wendy A Jobling; Benjamin P C Chen; David J Chen; John M Sedivy
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

View more
  35 in total

1.  Nature vs nurture: interplay between the genetic control of telomere length and environmental factors.

Authors:  Yaniv Harari; Gal-Hagit Romano; Lior Ungar; Martin Kupiec
Journal:  Cell Cycle       Date:  2013-09-26       Impact factor: 4.534

2.  Dyskeratosis congenita caused by a novel TERT point mutation in siblings with pancytopenia and exudative retinopathy.

Authors:  Akshay Sharma; Kasiani Myers; Zhan Ye; John D'Orazio
Journal:  Pediatr Blood Cancer       Date:  2014-07-25       Impact factor: 3.167

3.  Telomere length variation: A potential new telomere biomarker for lung cancer risk.

Authors:  Bing Sun; Ying Wang; Krishna Kota; Yaru Shi; Salaam Motlak; Kepher Makambi; Christopher A Loffredo; Peter G Shields; Qin Yang; Curtis C Harris; Yun-Ling Zheng
Journal:  Lung Cancer       Date:  2015-03-20       Impact factor: 5.705

4.  Association between regulator of telomere elongation helicase 1 polymorphism and susceptibility to glioma.

Authors:  Shujun Pei; Feng Zhao; Junle Liu; Qiang Fu; Peizhong Shang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.

Authors:  Florian Zink; Simon N Stacey; Gudmundur L Norddahl; Michael L Frigge; Olafur T Magnusson; Ingileif Jonsdottir; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Sigurjon A Gudjonsson; Julius Gudmundsson; Jon G Jonasson; Laufey Tryggvadottir; Thorvaldur Jonsson; Agnar Helgason; Arnaldur Gylfason; Patrick Sulem; Thorunn Rafnar; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Gisli Masson; Augustine Kong; Kari Stefansson
Journal:  Blood       Date:  2017-05-08       Impact factor: 22.113

6.  Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita.

Authors:  Hemanth Tummala; Amanda Walne; Laura Collopy; Shirleny Cardoso; Josu de la Fuente; Sarah Lawson; James Powell; Nicola Cooper; Alison Foster; Shehla Mohammed; Vincent Plagnol; Thomas Vulliamy; Inderjeet Dokal
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

7.  mRNA deadenylation and telomere disease.

Authors:  Philip J Mason; Monica Bessler
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

Review 8.  Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Authors:  João Vinagre; Vasco Pinto; Ricardo Celestino; Marta Reis; Helena Pópulo; Paula Boaventura; Miguel Melo; Telmo Catarino; Jorge Lima; José Manuel Lopes; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

Review 9.  Telomere biology and translational research.

Authors:  Philip J Mason; Nieves Perdigones
Journal:  Transl Res       Date:  2013-09-23       Impact factor: 7.012

10.  Effects of TIN2 on telomeres and chromosomes in the human gastric epithelial cell line GES-1.

Authors:  Fan Fu; Hua Hu; Shuai Yang; Xiaoqiu Liang
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.